DK0458064T3 - Stabilisering af somatotropiner ved modificering af cysteinrester - Google Patents

Stabilisering af somatotropiner ved modificering af cysteinrester

Info

Publication number
DK0458064T3
DK0458064T3 DK91106224.8T DK91106224T DK0458064T3 DK 0458064 T3 DK0458064 T3 DK 0458064T3 DK 91106224 T DK91106224 T DK 91106224T DK 0458064 T3 DK0458064 T3 DK 0458064T3
Authority
DK
Denmark
Prior art keywords
polypeptides
proteins
cysteine residues
somatotropins
stabilization
Prior art date
Application number
DK91106224.8T
Other languages
Danish (da)
English (en)
Inventor
Brian Lee Buckwalter
Susan Mancini Cady
Michael Joseph Daley
Hong-Ming Shieh
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0458064T3 publication Critical patent/DK0458064T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK91106224.8T 1990-05-04 1991-04-18 Stabilisering af somatotropiner ved modificering af cysteinrester DK0458064T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51904790A 1990-05-04 1990-05-04

Publications (1)

Publication Number Publication Date
DK0458064T3 true DK0458064T3 (da) 1998-04-27

Family

ID=24066559

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91106224.8T DK0458064T3 (da) 1990-05-04 1991-04-18 Stabilisering af somatotropiner ved modificering af cysteinrester

Country Status (17)

Country Link
EP (1) EP0458064B1 (fr)
JP (1) JPH069696A (fr)
KR (1) KR100213455B1 (fr)
AT (1) ATE163431T1 (fr)
AU (1) AU639324B2 (fr)
CA (1) CA2041742A1 (fr)
DE (1) DE69128944T2 (fr)
DK (1) DK0458064T3 (fr)
ES (1) ES2113354T3 (fr)
FI (1) FI912144L (fr)
GR (1) GR3026436T3 (fr)
IE (1) IE911511A1 (fr)
IL (1) IL97932A (fr)
NO (1) NO911752L (fr)
NZ (1) NZ237959A (fr)
PT (1) PT97539B (fr)
ZA (1) ZA913359B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB9100381D0 (en) * 1991-01-09 1991-02-20 Erba Carlo Spa Human bfgf derivatives,their analogs and process for their production
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
EP0618927A4 (fr) * 1991-12-10 1995-05-24 Tanox Biosystems Inc Cytokines dotees d'un residu de cysteine non apparie et leurs produits de conjugaison.
JPH08506095A (ja) * 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
EP0622394A1 (fr) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Modification reversible de composés contenant du soufre par des glycols de polyalkylène et leur utilisation
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
WO2002055532A2 (fr) * 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees
HRP20040448A2 (en) * 2001-11-20 2006-02-28 Pharmacia Corporation Method for detecting cells with numerical chromosomal abnormalities
RS20050502A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
EP1673464A2 (fr) * 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugaison de peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2007041614A2 (fr) 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation
EP2102355B1 (fr) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof

Also Published As

Publication number Publication date
IL97932A0 (en) 1992-06-21
EP0458064A3 (en) 1992-06-17
KR910020032A (ko) 1991-12-19
ES2113354T3 (es) 1998-05-01
DE69128944T2 (de) 1998-06-25
PT97539A (pt) 1992-02-28
NO911752L (no) 1991-11-05
GR3026436T3 (en) 1998-06-30
AU639324B2 (en) 1993-07-22
FI912144A0 (fi) 1991-05-03
DE69128944D1 (de) 1998-04-02
CA2041742A1 (fr) 1991-11-05
JPH069696A (ja) 1994-01-18
PT97539B (pt) 1998-08-31
NZ237959A (en) 1994-05-26
FI912144A7 (fi) 1991-11-05
EP0458064B1 (fr) 1998-02-25
KR100213455B1 (ko) 1999-08-02
FI912144L (fi) 1991-11-05
AU7607591A (en) 1991-11-07
EP0458064A2 (fr) 1991-11-27
ATE163431T1 (de) 1998-03-15
IL97932A (en) 1998-02-22
NO911752D0 (no) 1991-05-03
IE911511A1 (en) 1991-11-06
ZA913359B (en) 1992-03-25

Similar Documents

Publication Publication Date Title
DK0458064T3 (da) Stabilisering af somatotropiner ved modificering af cysteinrester
DK0469074T3 (da) Cystein-tilsatte varianter af IL-3 og kemiske modifikationer deraf
EP0355460A3 (fr) Stabilisation de somatotropines par modification du résidu cystéine en utilisant un site de mutagénèse dirigée ou par modification chimique
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
SE7705432L (sv) Polypeptid och sett for dess framstellning
DK97987D0 (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
DK447788A (da) Apparat til applikation af implantater
NO932148L (no) Fusjonspolypeptider
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
DK0547064T3 (da) Proteaseresistent PDGF og anvendelsesfremgangsmåde
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
DE69322268D1 (de) Stabile zusammensetzung von polypeptiden
DK0533408T3 (da) Kosmetik og farmaceutika indeholdende extensiner
SE8200757L (sv) Biologiskt aktiva peptider
DK5693D0 (da) Kloning og fremstilling af polypeptidanaloger af humant fibronektins cellebindingsomraade, polypeptidanaloger af humant fibronektins cellebindingsomraade og anvendelse af saadanne polypeptidanaloger
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
DE59008844D1 (de) Benzylselenobenzamide von Aminopyridinen und Picolylaminen.
SE9101586D0 (sv) Modified thioredoxin and its use
ES2061809T3 (es) Un metodo para preparar un derivado de calcitonina.
NO873751L (no) Lymfocytt-aktiverende polypeptider.
FI906112A7 (fi) Menetelmiä ja koostumuksia nisäkkäiden infektioiden käsittelemiseksi k äyttämällä lääkkeitä, jotka käsittävät pistiäisten myrkkyä, sen protei ini- tai polypeptidiainesosia tai näiden porteiini- tai polypeptidiain eosien analogeja
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat